GRI Bio, Inc. (GRI) Stock Forecast
GRI analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $18.50 average of analyst targets
- Upside to target
- +1,240.6% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.84
- 52-week range
- $1.38 – $63.28
GRI analyst ratings
2 analystsNumber of analysts at each rating.
GRI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GRI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.84 | −$0.93 | −$0.75 | −$35.84 | +97.7% | 2 |
| Current fiscal year (2026) | −$3.90 | −$4.13 | −$3.66 | −$121.80 | +96.8% | 2 |
| Next fiscal year (2027) | −$2.00 | −$3.79 | −$0.21 | −$3.90 | +48.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GRI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
GRI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GRI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.08 | −$1.08 | −$0.84 | −$0.84 | −$0.84 | −22.2% | 2 up · 0 down |
| Current fiscal year (2026) | −$4.77 | −$4.77 | −$3.90 | −$3.90 | −$3.90 | −18.3% | 2 up · 0 down |
| Next fiscal year (2027) | −$2.54 | −$2.54 | −$2.00 | −$2.00 | −$2.00 | −21.1% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GRI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GRI beat in 5 of 8.
What analysts expect from GRI
2 analysts cover GRI Bio; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.50, 1,240.6% above the latest close of $1.38. Analysts expect earnings of −$3.90 per share for 2026, +96.8% from a year earlier. For 2027 the average estimate is −$2.00 per share. GRI Bio beat the EPS estimate in 5 of the last 8 quarters.
Related: GRI income statement, GRI key metrics, GRI chart. See the GRI stock overview for the latest quote and news.
GRI forecast FAQ
What is GRI Bio's price target?
The average analyst price target for GRI Bio is $18.50, 1,240.6% above the latest close of $1.38.
Is GRI Bio a buy, hold or sell?
Of 2 analysts covering GRI Bio, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is GRI Bio's EPS forecast?
Analysts forecast −$3.90 per share for 2026 (range −$4.13 to −$3.66); for 2027 the estimate is −$2.00.
When does GRI Bio report earnings?
GRI Bio is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.84.
Does GRI Bio usually beat earnings estimates?
GRI Bio reported EPS at or above the analyst estimate in 5 of the last 8 quarters.